ALTSTATION.IO

West Pharmaceutical Services, Inc. (WST) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$243.94

Change

+5.32%

Market Cap

$17.55B

Avg Volume

820.5K

Company Overview

West Pharmaceutical Services, Inc. (WST) focuses on designing and manufacturing containment and delivery systems for injectable drugs and healthcare products. Their offerings include stoppers, seals, syringe components, and advanced drug delivery systems that cater primarily to biologic, generic, and pharmaceutical companies. They also provide contract manufacturing services for devices used in various medical applications. Headquartered in Exton, Pennsylvania, West operates globally, servicing clients across North America, Europe, the Middle East, Africa, and the Asia Pacific.

West holds a competitive position as a leader in the medical instruments and supplies sector, particularly in injectable drug delivery systems. Their edge comes from a diverse product line that features custom solutions and advanced technologies to enhance drug safety and efficacy. Key competitors include companies like Becton Dickinson and Terumo, which makes the market dynamic and competitive. However, West’s strong focus on innovation and regulatory expertise allows it to maintain a favorable position.

Currently, West is showing growth momentum, driven by increasing demand for injectable therapies and high-barrier entry markets. Recent milestones include strategic investments in manufacturing capabilities to enhance production efficiency and meet rising demand. Their ongoing initiatives in developing integrated solutions and expanding services further solidify their market position and address evolving customer needs. Overall, West is capitalizing on trends in healthcare that prioritize safety and efficiency in drug delivery.

Key Financials

Market Cap

$17.55B

Revenue

$3.02B

EBITDA

$801.40M

Gross Margin

35.6%

Profit Margin

16.3%

Revenue Growth

7.7%

Total Cash

$628.50M

Total Debt

$303.00M

Free Cash Flow

$251.19M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

36.19

Forward P/E

31.36

Beta

1.19

52-Week High

$332.47

52-Week Low

$187.43

EPS

$6.74

50-Day Avg

$265.15

200-Day Avg

$247.66

Price/Book

5.75

Technical Analysis

Over the past 52 weeks, West Pharmaceutical Services, Inc. (WST) has exhibited a bearish trend, declining from around $314 in February to its current price of $243.94, reflecting a significant drop of approximately 22.9%. The key resistance level appears to be around $248.95, which the stock has struggled to maintain recently, while solid support can be identified near $225, serving as a potential floor in this downward trajectory. Notably, the chart reveals a series of lower highs and lower lows, confirming a downward price pattern, particularly evident from June through February. In the last few weeks, there has been a slight uptick from the recent low, indicating some momentary bullish momentum, though it remains weak and uncertain. Currently, the price at $243.94 situates the stock well within its 52-week range, suggesting a cautious outlook as it hovers close to its support level, which could imply potential further declines if it cannot break through the resistance around $248.95.

Recent News and Developments

Here’s a summary of the latest news and developments for West Pharmaceutical Services, Inc

(WST) stock over the past week, from January 31, 2026, to February 7, 2026:

1. West Pharmaceutical Services Unveils “Synchrony S1” Syringe System

West Pharmaceutical Services has introduced its new “Synchrony S1” Syringe System. This innovative offering aims to streamline prefillable syringe (PFS) packaging development, potentially reducing complexity and shortening timelines for drug developers, particularly for emerging biotechnology companies preparing for clinical trials.

2. Anticipation Builds for Q4 2025 Earnings Report

West Pharmaceutical Services is scheduled to release its fourth-quarter and full-year 2025 earnings results on Thursday, February 12, 2026. Analysts are anticipating the company to report quarterly earnings of $1.83 per share, which would represent a modest year-over-year increase of 0.6%, with revenues expected to be around $794.26 million, up 6.1% from the prior year’s quarter.

Market Sentiment and Analyst Recommendations

Bull Case

West has a clear tailwind from the prefilled syringe market, which is growing as pharma companies shift toward injectable drug delivery. The new Synchrony S1 system is a legitimate competitive advantage — it reduces complexity and shortens development timelines for biotech clients, which translates to recurring revenue and customer lock-in. Revenue growth of 7.7% is steady, and with 14 analysts calling this a strong buy and a median price target of $350, the upside to current levels is substantial — roughly 43% from $243.94. The balance sheet is solid with $628.5M in cash against only $303M in debt, giving management flexibility for M&A or shareholder returns. Most importantly, the company is positioned in a structural growth market. As the industry continues consolidating around prefilled solutions, West benefits from both volume and pricing power.

Bear Case

The P/E of 36.19 is expensive for a company growing revenue at just 7.7%. That’s a growth-to-multiple mismatch that leaves no room for disappointment. The stock is down 22.9% from its February 2025 high of $314, and the chart shows a clear downtrend with lower highs and lower lows through June-February — this isn’t noise, it’s institutional selling. Support is only at $225, meaning another 8% downside is plausible if momentum breaks. Q4 earnings expectations are modest at $1.83 per share with just 0.6% year-over-year growth, which is weak for a company trading at this multiple. Macro headwinds in healthcare spending and potential pricing pressure from large pharma customers could compress margins further. The analyst consensus is bullish, but that often comes late in cycles.

What to Watch

The Q4 2025 earnings on February 12 are critical — watch whether the company beats or misses the $1.83 EPS estimate and $794.26M revenue guidance. If they disappoint, the stock will likely test $225 support. Track Synchrony S1 adoption rates in the next two quarters; this product needs to show real traction and customer wins, not just announcements. Monitor the $248.95 resistance level closely — if WST can’t break above it decisively over the next 4-6 weeks, the downtrend likely resumes. Watch for any margin pressure or commentary on pricing from large pharma customers during earnings calls. Finally, keep an eye on the analyst price target range ($285-$375) and whether the consensus shifts; if more analysts downgrade or lower their targets post-earnings, that’s a signal the bull thesis is cracking.

Analyst Consensus

STRONG BUY

Based on 14 analyst opinions

Low Target

$285.00

Mean Target

$340.71

High Target

$375.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

10,600

Earnings & Dividends

Next Earnings

Feb 12, 2026

EPS (Trailing)

$6.74

Dividend Yield

38.0%

Payout Ratio

12.4%

Frequently Asked Questions

Is WST a good stock to buy?

West Pharmaceutical Services, Inc. (WST) has a strong analyst recommendation of “STRONG BUY” with a target price of $340.71, indicating significant upside potential from its current price of $243.94. Considering the robust fundamentals and growth potential, it’s a solid buy for long-term investors.

What is WST’s price target?

Analysts have set a price target of $340.71 for WST. This suggests a potential upside of about 39.5% from the current price, making it an attractive option for investors looking for growth.

Does WST pay a dividend?

Yes, WST has a dividend yield of 38.0%. This attractive yield is a strong incentive for income-focused investors, although it’s worth noting that the payout ratio and sustainability should be assessed periodically.

What is WST’s market cap?

West Pharmaceutical Services has a market cap of $17.55 billion. This positions the company as a substantial player in the healthcare sector, particularly within the medical instruments and supplies industry.

What are the P/E ratios for WST?

WST currently has a P/E ratio of 36.19 and a forward P/E of 31.36. These figures suggest that the stock is trading at a premium, reflecting investor confidence in its future growth prospects.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.